Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors
Neurocrine Biosciences (Nasdaq: NBIX) announced the appointment of Johanna Mercier to its Board of Directors. Mercier, currently the Chief Commercial Officer at Gilead Sciences, brings extensive experience from her 25-year tenure at Bristol Myers Squibb, where she led successful commercial strategies, particularly in oncology. Her expertise is anticipated to enhance the company's direction in developing treatments for neurological and endocrine disorders. The announcement underscores the company's commitment to strengthening its leadership team.
- Johanna Mercier's extensive experience in the biopharmaceutical industry is expected to bring valuable insights and commercial strategies to Neurocrine.
- Her previous success in launching treatments in oncology positions her well to support Neurocrine's product portfolio.
- Concerns about the potential continuity and integration of new leadership into existing company strategies.
SAN DIEGO, April 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial Officer of Gilead Sciences, with responsibility for the global commercialization of Gilead's medicines.
"We are pleased to add Johanna Mercier to the Board of Directors at Neurocrine Biosciences," said William H. Rastetter, Chairman of the Board of Neurocrine Biosciences. "Johanna is an accomplished commercial leader and her extensive global experience within the biopharmaceutical industry will be invaluable to Neurocrine and our Board of Directors."
Johanna joined Gilead Sciences in 2019 as Chief Commercial Officer after 25 years at Bristol Myers Squibb, where she served in a number of executive leadership positions, gaining broad experience across geographies and in all aspects of the commercial business. In her time at Bristol Myers Squibb, she drove strong commercial strategy and performance with multiple launches that changed the standard of care in melanoma and renal cancers.
Johanna holds a bachelor's degree in biology from the University of Montreal and an MBA from Concordia University. She is a member of the board of the University of Southern California's Leonard D. Schaeffer Center for Health Policy and Economics. Johanna is also a member of World 50.
About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-appointment-of-johanna-mercier-to-board-of-directors-301270422.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
Who is Johanna Mercier and what is her role at Neurocrine Biosciences?
What experience does Johanna Mercier bring to Neurocrine Biosciences?
What impact could Johanna Mercier's appointment have on Neurocrine Biosciences?
When was Johanna Mercier appointed to the Board of Directors of Neurocrine Biosciences?
